Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs [Beta]-Cell Function

Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice effectively treats autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and immunologic effects of rapamycin/IL-2 combination therapy in type 1 diabetic (T1D) patients. Nine T1D subjects were treated with 2-4 m...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2012-09, Vol.61 (9), p.2340
Hauptverfasser:	Long, S Alice, Rieck, Mary, Sanda, Srinath, Bollyky, Jennifer B, Samuels, Peter L, Goland, Robin, Ahmann, Andrew, Rabinovitch, Alex, Aggarwal, Sudeepta, Phippard, Deborah, Turka, Laurence A, Ehlers, Mario R, Bianchine, Peter J, Boyle, Karen D, Adah, Steven A, Bluestone, Jeffrey A, Buckner, Jane H, Greenbaum, Carla J
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trials Cytokines Diabetes Flow cytometry Growth factors Hyperglycemia Laboratories Peptides Proteins Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!